Phase 4 N=1,291 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Scabies · Yaws · Impetigo
Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Anakinra for Inflammatory Pustular Skin Diseases
Sneddon-Wilkinson · Acrodermatitis Continua of Hallopeau · Pustular Psoriasis
Primary: Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50) — 7…
Phase 4 N=7 Predicting Inflammatory Skin Disease Response to IL-23 Blockade
Psoriasis Vulgaris
Primary: Psoriasis Area and Severity Index (PASI) Score — 3.9 score on a scale
Phase 1 N=5 Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
Atopic Dermatitis
Primary: Relative Staphylococcus Aureus Abundance — 0.13; 12.2 ratio to baseline S. aureus abundance
N/A N=20 Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study
Postoperative Wound Infection Deep Incisional Surgical Site · Prosthesis and Implants · Surgical Site Infection
Primary: Number of Participants With Bacterial Growth Before and After Photodynamic Treatment and After Skin Antisepsis — 10; 10; 3; NA Participants
Phase 4 N=70 Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
Atopic Dermatitis · Secondary Infection
Primary: Bacteriological Culture — 13; 3; 16; 5 participants
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
N/A N=368 Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
Dermatitis, Atopic
Primary: Seroprotection, Non-Atopic Dermatitis (AD), Intradermal vs. Moderate to Severe Atopic Dermatitis, Intradermal - Influenza B — 34.4; 22.5 percentage of participants…
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
Phase 2 N=47 Tofacitinib for Immune Skin Conditions in Down Syndrome
Down Syndrome · Alopecia Areata · Atopic Dermatitis / Eczema
Primary: Number of Serious Adverse Events (SAE) Definitely Related to Tofacitinib Treatment. — 0 Serious Adverse Events
N/A N=50 Spread of Dermatophytes Among Families
Onychomycosis · Tinea Pedis
Primary: Dermatophyte Species Distribution — 50; 37; 5; 12 isolates
Phase 2 N=19 A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants
Phase 2 N=20 The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
Secondarily Infected Traumatic Lesions (SITL) · Impetigo
Primary: TD1414 Serum Concentration by Timepoint — 624.3; 864.1; 1195.7; 888.4 pg/mL
Phase 2 N=65 Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
Impetigo · Secondarily Infected Traumatic Lesions
Primary: Participants With Clinical Cure According to Investigator's Assessment — 167; 184; 174; 36 Participants
N/A N=148 ObservAtional Study to Investigate Surgical Site Infection in Ulcerated Skin Cancers
Skin Cancer
Primary: To Ascertain the Percentage of Surgical Site Infections Following Excision of Ulcerated Skin Tumours in Dermatology Departments. — 35 Participants
Phase 3 N=36 Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients
Varicella
Primary: Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample — 6.49; 6.46; 6.07; 6.02 VZV genome copies per sample
N/A N=133 Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents
Xerosis Cutis
Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale
N/A N=95 Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
Zika · Dengue · Malaria
Primary: Number of Differentially Expressed Genes Between Bitten (Case) Versus Unbitten (Control) Skin for Each of the Three Vector Groups — 18; NA; 1; NA number of…
Early Phase 1 N=13 An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
Ichthyosis
Primary: Reduction in Total Ichthyosis Severity Score — -12.2 units on a scale
Phase 2 N=60 Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change
Phase 4 N=11 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Psoriasis
Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…
Phase 2 N=52 A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Percent Change From Baseline in Total Abscess and Inflammatory Nodule Count at Week 12 — -34.7; -38.8 percent change
Phase 3 N=657 To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions
Secondarily Infected Traumatic Skin Lesions
Primary: Proportion of Subjects in Each Treatment Group With Clinical Cure (Defined as a Skin Infection Rating Scale (SIRS) Score of 0 for All Signs and Symptoms) — 145; 169; 124…
Phase 2 N=15 Topical NanoDox® for Atopic Dermatitis
Dermatitis, Atopic
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0 Participants
Phase 3 N=51 A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin
Eczema
Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001
Phase 2 N=41 Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change
Phase 4 N=17 Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
Atopic Dermatitis · Atopic Dermatitis Eczema · Eczema
Primary: Percent Change in CD4+ T Effector Cells Expressing IL4 in Dupilumab-treated Subjects at Week 12 vs Week 0 — 68.4; 100.0 Percent change
Phase 1 N=15 Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients
Atopic Dermatitis Eczema
Primary: Relative Abundance of Staphylococcus Aureus Compared to Baseline — 0.106; 12.9 Relative abundance of S. aureus
Phase 2 N=260 Leprosy Skin Test Antigens Trial
Leprosy
Primary: Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram — 0; 3; 1; 5…
Phase 2 N=16 Topical Ruxolitinib in Chronic Hand Dermatitis
Chronic Hand Dermatitis
Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants